Stock listing

Frankfurt:2H51 Ocugen, Inc. Aktie

German listing (Frankfurt) of Ocugen, Inc. · home listing NASDAQ:OCGN

Follow Ocugen, Inc. into a list and get an email when it puts out news.

Share price · FWB:2H51

€0.639 EUR -0.051 (-7.4%)

Close on Oct 30, 2026

Day range
€0.639 – €0.700 EUROct 30, 2026
Ocugen, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:OCGN · Home$0.703 USD-0.041 (-5.6%)5,370,566$0.746$0.760$0.691$0.744Close on Oct 30, 2026
Frankfurt:2H51€0.639 EUR-0.051 (-7.4%)—€0.657€0.700€0.639€0.690Close on Oct 30, 2026
Ticker
Frankfurt:2H51
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Ocugen (NASDAQ:OCGN) Q3 2026 Earnings Call

    Wed, Nov 04, 2026 · 8:30 AM ET

    Register

Replays

  • Ocugen (NASDAQ:OCGN) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:30 AM ET

    Watch Transcript

  • Ocugen (NASDAQ:OCGN) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 8:30 AM ET

    Watch Transcript

  • Ocugen (NASDAQ:OCGN) Q4 2025 Earnings Call

    Wed, Mar 04, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Ocugen to Participate in Upcoming November Investor and Industry Conferences

Oct 29, 2026

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

Oct 22, 2026

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Oct 14, 2026

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

Oct 6, 2026

Ocugen to Participate in Upcoming Scientific Conferences

Sep 30, 2026

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Sep 29, 2026

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Sep 25, 2026

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Sep 1, 2026

Ocugen to Participate in Upcoming September Investor and Industry Conferences

Aug 25, 2026

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Aug 6, 2026

All Ocugen, Inc. news

Decks

Ocugen, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
39 in the last 12 months · 274 in all · newest Oct 29, 2026 · oldest 2019
Calls
22 calls with a replay · 22 with a transcript · latest Aug 6, 2026
Decks
74 decks · latest Oct 15, 2026

Where Ocugen, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:OCGN · Home listingNASDAQUnited StatesUSD
gettex:2H51gettexGermanyEUR
Tradegate:2H51TradegateGermanyEUR
LS Exchange:A2PSZHLS ExchangeGermanyEUR
BMV:OCGNBMVMexicoMXN
Lang & Schwarz:A2PSZHLang & SchwarzGermanyEUR
Frankfurt:2H51 · This pageFrankfurtGermanyEUR
Stuttgart:2H51StuttgartGermanyEUR
Munich:2H51MunichGermanyEUR
Dusseldorf:2H51DusseldorfGermanyEUR
BOATS:OCGNBOATSUnited StatesUSD
BIVA:OCGNBIVAMexicoMXN
Hamburg:2H51HamburgGermanyEUR
Hanover:2H51HanoverGermanyEUR
Xetra:2H51XetraGermanyEUR

Log in to ask 6ix AI your own questions about Ocugen, Inc.